Statin Use and Risk of Colorectal Cancer in a Cohort of Middle-Aged Men in the US

详细信息    查看全文

• 作者：E. Dawn Flick (1) (3)
  Laurel A. Habel (1)
  K. Arnold Chan (3) (4)
  Reina Haque (2)
  Virginia P. Quinn (2)
  Stephen K. Van Den Eeden (1)
  Barbara Sternfeld (1)
  Endel J. Orav (5)
  John D. Seeger (3) (4)
  Charles P. Quesenberry Jr (1)
  Dr Bette J. Caan (1)
  
• 刊名：Drugs
• 出版年：2009
• 出版时间：July 2009
• 年：2009
• 卷：69
• 期：11
• 页码：1445-1457
• 全文大小：157KB
• 参考文献：1. American Cancer Society. Cancer facts and figures 2007. Atlanta (GA): American Cancer Society, 2007
  2. Agarwal B, Halmos B, Feoktistov AS, et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 2002; 23(3): 521- dx.doi.org/10.1093/carcin/23.3.521">CrossRef
  3. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999; 117(4): 838-7 dx.doi.org/10.1016/S0016-5085(99)70342-2">CrossRef
  4. Alonso DF, Farina HG, Skilton G, et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998; 50(1): 83-3 dx.doi.org/10.1023/A:1006058409974">CrossRef
  5. Carlberg M, Dricu A, Blegen H, et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface: evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth. J Biol Chem 1996; 271(29): 17453-2 dx.doi.org/10.1074/jbc.271.29.17453">CrossRef
  6. Chan KKW, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10-
  7. Kusama T, Mukai M, Iwasaki T, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-7 dx.doi.org/10.1053/gast.2002.31093">CrossRef
  8. Lee SJ, Ha MJ, Lee J, et al. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/ CIP1) in human prostate carcinoma cells. J Biol Chem 1998; 273(17): 10618-3 dx.doi.org/10.1074/jbc.273.17.10618">CrossRef
  9. Matar P, Rozados VR, Roggero EA, et al. Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother Radiopharm 1998; 13(5): 387-3 dx.doi.org/10.1089/cbr.1998.13.387">CrossRef
  10. Muller C, Bockhorn AG, Klusmeier S, et al. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 1998; 12(3): 717-3
  11. Narisawa T, Morotomi M, Fukaura Y, et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996; 87(8): 798-04 dx.doi.org/10.1111/j.1349-7006.1996.tb02103.x">CrossRef
  12. Padayatty SJ, Marcelli M, Shao TC, et al. Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab 1997; 82: 1434- dx.doi.org/10.1210/jc.82.5.1434">CrossRef
  13. Park HJ, Kong D, Iruela-Arispe L, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91: 143-0 dx.doi.org/10.1161/01.RES.0000028149.15986.4C">CrossRef
  14. Ukomada C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem 2003; 278(44): 43586-4 dx.doi.org/10.1074/jbc.M307194200">CrossRef
  15. Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation 2002; 105(6): 739-5 dx.doi.org/10.1161/hc0602.103393">CrossRef
  16. Wong WW-L, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508-9 dx.doi.org/10.1038/sj.leu.2402476">CrossRef
  17. Narisawa T, Fukaura Y, Tanida N, et al. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 1996; 180(2): 131- dx.doi.org/10.1620/tjem.180.131">CrossRef
  18. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev 2005; 14(8): 1897- dx.doi.org/10.1158/1055-9965.EPI-05-0027">CrossRef
  19. Armitage J, Collins R, Bowman L, et al. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20 536 high-risk people: a randomised placebo-controlled trial [ISRCTN484 89393]. Heart Protection Study Collaborative Group. BMC Med 2005; 3: 6
  20. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001- dx.doi.org/10.1056/NEJM199610033351401">CrossRef
  21. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364: 771- dx.doi.org/10.1016/S0140-6736(04)16936-5">CrossRef
  22. Probstfield JL, Davis BR. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288(23): 2998-007
  23. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-0 dx.doi.org/10.1016/S0140-6736(02)11600-X">CrossRef
  24. Simes RJ, Hunt D, Kirby A, et al. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379-7 dx.doi.org/10.1016/S0140-6736(02)08351-4">CrossRef
  25. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87(9): 1074- dx.doi.org/10.1016/S0002-9149(01)01464-3">CrossRef
  26. Gwyn K, Sinicrope FA. Chemoprevention of colorectal cancer. Am J Gastroenterology 2002; 97(1): 13-1 dx.doi.org/10.1111/j.1572-0241.2002.05435.x">CrossRef
  27. Wei JT, Mott LA, Baron JA, et al. Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas. Polyp Prevention Study Group. Cancer Epidemiol Biomarkers Prev 2005; 14: 1026- dx.doi.org/10.1158/1055-9965.EPI-03-0080">CrossRef
  28. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363- dx.doi.org/10.1001/archinte.160.15.2363">CrossRef
  29. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007; 99: 32-0 dx.doi.org/10.1093/jnci/djk003">CrossRef
  30. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643- dx.doi.org/10.1002/ijc.20758">CrossRef
  31. Graaf MR, Beiderbeck AB, Egberts ACG, et al. The risk of cancer in users of statins. J Clin Oncol 2004; 22(12): 2388-4 dx.doi.org/10.1200/JCO.2004.02.027">CrossRef
  32. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007; 115: 27-3 dx.doi.org/10.1161/CIRCULATIONAHA.106.650176">CrossRef
  33. Vinogradova Y, Hippisley-Cox J, Coupland C, et al. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007; 133(2): 393-02 dx.doi.org/10.1053/j.gastro.2007.05.023">CrossRef
  34. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 2007; 121(6): 1325-0 dx.doi.org/10.1002/ijc.22796">CrossRef
  35. Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 992184-2 dx.doi.org/10.1056/NEJMoa043792">CrossRef
  36. Boudreau DM, Koehler E, Rulyak SJ, et al. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17(11): 3076-0 dx.doi.org/10.1158/1055-9965.EPI-08-0095">CrossRef
  37. Jacobs EJ, Rodriguez C, Brady KA, et al. Cholesterollowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006; 98: 69-2 dx.doi.org/10.1093/jnci/djj006">CrossRef
  38. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635- dx.doi.org/10.1038/sj.bjc.6601566">CrossRef
  39. Bonovas S, Filioussi K, Flordellis CS, et al. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007; 25(23): 3462- dx.doi.org/10.1200/JCO.2007.10.8936">CrossRef
  40. Enger SM, Van den Eeden SK, Sternfeld B, et al. California Men’s Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health 2006; 6: 172 dx.doi.org/10.1186/1471-2458-6-172">CrossRef
  41. Oehrli MD, Quesenberry Jr CP, Leyden W. Northern California Cancer Registry: 2006 annual report on trends, incidence, and outcomes. Oakland (CA): Kaiser Permanente Northern California Cancer Registry, 2006 Nov
  42. Haque R, Chiu V, Mehta KR, et al. An automated data algorithm to distinguish screening and diagnostic colorectal cancer endoscopy exams. J Natl Cancer Inst Monogr 2005; 35: 116- dx.doi.org/10.1093/jncimonographs/lgi049">CrossRef
  43. Janssen A, Maier TJ, Schiffmann S, et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol 2006; 540(1-): 24-3 dx.doi.org/10.1016/j.ejphar.2006.04.030">CrossRef
  44. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57(14): 2909-5
  45. Watson AJM. An overview of apoptosis and the prevention of colorectal cancer. Clin Rev Oncol Hematol 2006; 57(2): 107-1 dx.doi.org/10.1016/j.critrevonc.2005.06.005">CrossRef
  46. Feleszko W, Jalili A, Olszewska D, et al. Synergistic interaction between highly specific cyclooxygenase-2-inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep 2002; 9(4): 879-5
  47. Reddy BS, Wang CX, Kong AN, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006; 66(8): 4542- dx.doi.org/10.1158/0008-5472.CAN-05-4428">CrossRef
  48. Setoguchi S, Avorn J, Schneeweiss S. Statins and risk of colorectal cancer. N Engl J Med 2005; 353: 952 dx.doi.org/10.1056/NEJMc051738">CrossRef
  49. Selby JV, Smith DH, Johnson ES, et al. Kaiser Permanente medical care program. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons, Ltd, 2005: 241-9
  
• 作者单位：E. Dawn Flick (1) (3)
  Laurel A. Habel (1)
  K. Arnold Chan (3) (4)
  Reina Haque (2)
  Virginia P. Quinn (2)
  Stephen K. Van Den Eeden (1)
  Barbara Sternfeld (1)
  Endel J. Orav (5)
  John D. Seeger (3) (4)
  Charles P. Quesenberry Jr (1)
  Dr Bette J. Caan (1)
  
  1. Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, California, 94612, USA
  3. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
  4. i3 Drug Safety, Waltham, Massachusetts, USA
  2. Department of Research & Evaluation, Kaiser Permanente, Pasadena, California, USA
  5. Division of General Medicine, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
  

文摘

Background: Numerous modifiable factors have been associated with a reduced risk of colorectal cancer, including the chronic use of NSAIDs. Thus, it is biologically plausible that HMG-CoA reductase inhibitors (statins), therapeutic agents that also possess anti-inflammatory effects, are also associated with a lowered risk of colorectal cancer. Objective: To examine the association between statin use and the risk of colorectal cancer in a large cohort of middle-aged men enrolled in a prepaid, integrated health maintenance organization. Methods: We conducted a prospective cohort study of 69 115 Northern and Southern California Kaiser Permanente (KP) members aged 45-9 years who enrolled in the California Men’s Health Study in 2002-. Colorectal cancer cases were identified by linkage to the KP California Cancer Registries. Statin exposure, estimated from automated KP outpatient pharmacy records (available since 1991 in Southern California and 1994 in Northern California), was treated as time-varying. Cox proportional hazards regression analyses were used to estimate hazard ratios and 95% confidence intervals (CIs), while controlling for potential confounders. Results: During a maximum of 3.5 years of follow-up, 171 colorectal cancer cases were identified. Compared with nonuse, the adjusted hazard ratio for ever use of statins was 0.89 (95% CI 0.61, 1.30). The hazard ratio for statin use of ? years was 0.83 (95% CI 0.43, 1.63). The results did not differ markedly by type or severity of disease. There was also no evidence of effect modification by regular NSAID use. However, the stratified analyses were limited by small numbers. Conclusion: These findings provide little support for an association between the use of statins and the risk of colorectal cancer in men. There was some suggestion of a modest inverse association between statin use for ? years and risk of colorectal cancer; however, the possibility that this observation may be related to regular NSAID use cannot be ruled out.